Abstract
BackgroundDespite the proven efficacy of immune checkpoint inhibitor (ICI) therapy in the recurrent/metastatic setting for head and neck squamous cell carcinoma (HNSCC), clinical trials of ICI combined with curative-intent therapies...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have